{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:26:35Z","timestamp":1793571995230,"version":"4.5.0"},"reference-count":26,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2026,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>\n                      <jats:italic toggle=\"yes\">Introduction:<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>This retrospective study aims to assess the efficacy of infliximab by intravenous infusion in treating pediatric non-infectious uveitis, including as a second-line anti-tumor necrosis factor (TNF) for patients with insufficient control from adalimumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10807683261454323","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:52:22Z","timestamp":1779807142000},"page":"646-652","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Infliximab Is Efficacious for the Control of Pediatric Uveitis Including in Adalimumab-Refractory Patients"],"prefix":"10.1177","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2542-7329","authenticated-orcid":false,"given":"Ian R.","family":"Reekie","sequence":"first","affiliation":[{"name":"Birmingham Children\u2019s Hospital, Birmingham Women\u2019s and Children\u2019s NHS Foundation Trust, Birmingham, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ramm","sequence":"additional","affiliation":[{"name":"Birmingham Children\u2019s Hospital, Birmingham Women\u2019s and Children\u2019s NHS Foundation Trust, Birmingham, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslam","family":"Al-Abadi","sequence":"additional","affiliation":[{"name":"Birmingham Children\u2019s Hospital, Birmingham Women\u2019s and Children\u2019s NHS Foundation Trust, Birmingham, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7028-7014","authenticated-orcid":false,"given":"Sam P.","family":"Gurney","sequence":"additional","affiliation":[{"name":"Birmingham Children\u2019s Hospital, Birmingham Women\u2019s and Children\u2019s NHS Foundation Trust, Birmingham, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"William","sequence":"additional","affiliation":[{"name":"Birmingham Children\u2019s Hospital, Birmingham Women\u2019s and Children\u2019s NHS Foundation Trust, Birmingham, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000278"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.iio.0000155903.87679.c2"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2271988"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2016.1196713"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60244-4"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.08.024"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23871"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2015.07.001"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213131"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780361206"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1614160"},{"key":"e_1_3_2_13_1","article-title":"Clinical Commissioning Policy D12\/P\/b: Infliximab (Remicade) as Anti-TNF Alpha Treatment Option for Paediatric Patients with Severe Refractory Uveitis","author":"England NHS","year":"2015","unstructured":"12. England NHS. Clinical Commissioning Policy D12\/P\/b: Infliximab (Remicade) as Anti-TNF Alpha Treatment Option for Paediatric Patients with Severe Refractory Uveitis. NHS England Clinical Commissioning Policy 2015 .","journal-title":"NHS England Clinical Commissioning Policy"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.5584"},{"issue":"6","key":"e_1_3_2_15_1","first-page":"1043","article-title":"Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis Anti-adalimumab antibodies in JIA-uveitis","volume":"35","author":"Leinonen ST","year":"2017","unstructured":"14. Leinonen ST, , Aalto K, , Kotaniemi KM, et al. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis Anti-adalimumab antibodies in JIA-uveitis. Clin Exp Rheumatol 2017;35(6):1043\u20131046 .","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22214"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01158-6"},{"key":"e_1_3_2_19_1","unstructured":"18. Donachie PHJ Sparrow JM Johnston RL. Year 1 Annual Report-Piloting of the National Ophthalmology Database Audit Methodology National Ophthalmology Database Audit Acknowledgements. 2016. Available from: https:\/\/nodaudit.org.uk\/sites\/default\/files\/2022-06\/Annual%20Report%20%20Executive%20Summary%202016%20%20Year%201%20Piloting%20of%20the%20National%20Ophtha.pdf"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02795-3"},{"issue":"5","key":"e_1_3_2_21_1","first-page":"1146","article-title":"Tumor Necrosis Factor-\u03b1 Blocker in Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Second-line Agents: Results of a Multinational Survey","volume":"34","author":"Foeldvari I","year":"2007","unstructured":"20. Foeldvari I, , Nielsen S, , K\u00fcmmerle-Deschner J, et al. Tumor Necrosis Factor-\u03b1 Blocker in Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Second-line Agents: Results of a Multinational Survey. J Rheumatol 2007;34(5):1146\u20131150. Available from: http:\/\/www.jrheum.org","journal-title":"J Rheumatol"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu102"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3306"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13083"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-27.1.63"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i43.16014"},{"issue":"3","key":"e_1_3_2_27_1","first-page":"269","article-title":"Infectious complications of TNF-\u03b1 inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: Analysis of the Food and Drug Administration Adverse Event Reporting System","volume":"22","author":"Deepak P","year":"2013","unstructured":"26. Deepak P, , Stobaugh DJ, , Ehrenpreis ED. Infectious complications of TNF-\u03b1 inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: Analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis 2013;22(3):269\u2013276 .","journal-title":"J Gastrointestin Liver Dis"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261454323","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10807683261454323","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261454323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T21:37:18Z","timestamp":1793569038000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10807683261454323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,12,1]]}},"alternative-id":["10.1177\/10807683261454323"],"URL":"https:\/\/doi.org\/10.1177\/10807683261454323","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]}}}